Preparation of aryloxetanes and arylazetidines by use of an alkyl-aryl suzuki coupling

Organic Letters

Volumn 10, Issue 15, 2008, Pages 3259-3262

  Duncton, Matthew A J ^a   Estiarte, M Angels ^a   Tan, Darlene ^a   Kaub, Carl ^a   O'Mahony, Donogh J R ^a   Johnson, Russell J ^a   Cox, Matthew ^a   Edwards, William T ^a   Wan, Min ^a   Kincaid, John ^a   Kelly, Michael G ^a  

^a Evotec (USA)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZETIDINE DERIVATIVE; BENZENE DERIVATIVE; ETHER DERIVATIVE; OXETANE;

ARTICLE; SYNTHESIS;

AZETIDINES; BENZENE DERIVATIVES; ETHERS, CYCLIC;

EID: 49649125633     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol8011327     Document Type: Article

References (35)

1. Wuitschik, G.; Rogers-Evans, M.; Müller, K.; Fischer, H.; Wagner, B.; Schuler, F.; Polonchuk, L.; Carreira, E. M. Angew. Chem., Int. Ed. 2006, 45, 7736.
2. Leeson, P. D.; Springthorpe, B. Nat. Rev. Drug Disc. 2007, 6, 881, and references cited therein.
3. For examples of medicinally active oxetan-3-yl derivatives published prior to 2006, see: (a) Gibson, K. H.; Walter, E. R. H. GB 1976-51196.
4. (b) Edwards, P. N.; Girodeau, J. M. M. M. EP 1989-313384.
5. (c) Kuramoto, Y.; Okuhira, M.; Yatsunami, T. EP 1990-106007.
6. (d) Belley, M. L.; Leger, S.; Roy, P.; Xiang, Y. B.; Labelle, M.; Guay, D. EP 1991-309306.
7. (e) Crawley, G. C.; Dowell, R. I.; Edwards, P. N.; Foster, S. J.; McMillan, R. M.; Walker, E. R. H.; Waterson, D. J. Med. Chem. 1992, 35, 2600.
8. (f) Vaillancourt, V. A.; Larsen, S. D.; Nair, S. K. WO 2001070706.
9. (g) Homa, F. L.; Wathen, M. W.; Hopkins, T. A.; Thomsen, D. R. WO 2002006513.
10. (h) Wathen, M. W.; Wathen, L. K. WO 2004019933.
11. (i) Wathen, M. W.; Wathen, L. K. WO 2004019940.
12. (j) Allen, D. G.; Coe, D. M.; Cook, C. M.; Cooper, A. W. J.; Dowle, M. D.; Edlin, C. D.; Hamblin, J. N.; Johnson, M. R.; Jones, P. S.; Lindvall, M. K.; Mitchell, C. J.; Redgrave, A. J. WO 2004056823.
13. (k) Watanuki, S.; Koga, Y.; Moritomo, H.; Tsukamoto, I.; Kaga, D.; Okuda, T.; Hirayama, F.; Moritani, Y.; Takasaki, J. WO 2005009971.
14. (a) Searles, S.; Hummel, D. G.; Nukina, S.; Throckmorton, P. E. J. Am. Chem. Soc. 1960, 82, 2928.
15. (b) Castro, B.; Selve, C. Tetrahedron Lett. 1973, 45, 4459.
16. (c) Picard, P.; Leclercq, D.; Bats, J. P.; Moulines, J. Synthesis 1981, 550.
17. (d) Robinson, P. L.; Barry, C. N.; Kelly, J. W.; Evans, S. A. J. Am. Chem. Soc. 1985, 107, 5210.
18. (e) Katritzky, A. R.; Fan, W.; Li, Q. Youji Huaxue 1988, 8, 53.
19. For alternative synthesis of 3-aryloxetanes, see: (a) Yates, P.; Szabo, A. G. Tetrahedron Lett. 1965, 37, 485.
20. (b) Nerdel, F.; Kaminski, H.; Frank, D. Tetrahedron Lett. 1967, 39, 4973.
21. (c) Delmond, B.; Pommier, J. C.; Valade, J. Tetrahedron Lett. 1969, 41, 2089.
22. (d) Lewis, F. D.; Turro, N. J. J. Am. Chem. Soc. 1970, 92, 311.
23. (e) Delmond, B.; Pommier, J. C.; Valade, J. J. Organomet. Chem. 1973, 47, 337.
24. For a review see: Netherton, M. R.; Fu, G. C. In Topics in Organometallic Chemistry: Palladium in Organic Synthesis; Tsuji, J., Ed.; Springer: New York, 2005; pp 85-108.
25. (a) Zhou, J.; Fu, G. C. J. Am. Chem. Soc. 2004, 126, 1340.
26. (b) González-Bobes, F.; Fu, G. C. J. Am. Chem. Soc. 2006, 128, 5360.
27. (c) Saito, B.; Fu, G. C. J. Am. Chem. Soc. 2007, 129, 9602.
28. Clark, S. L.; Polak, R. J.; Wojtowicz, J. A. US 1966-557376.
29. Other conditions were not investigated.
30. (a) Malpass, J. R.; Handa, S.; White, R. Org. Lett. 2005, 7, 2759.
31. (b) White, R.; Malpass, J. R.; Handa, S.; Baker, R. S.; Broad, L. M.; Folly, L.; Mogg, A. Bioorg. Med. Chem. 2006, 16, 5493.
32. (c) Armstrong, A.; Bhonoah, Y.; Shanahan, S. E. J. Org. Chem. 2007, 72, 8019.
33. For a previous synthesis of protected arylazetidines using a palladium-mediated (Negishi) coupling of aryl halides with (1-(tert-butoxycarbonyl) azetidin-3-yl)zinc(II) iodide, see: (a) Billotte, S. Synlett 1998, 379.
34. Kumar, S.; Kassahun, K.; Tschirret-Guth, R. A.; Mitra, K.; Baillie, T. A. Curr. Opin. Drug Discovery 2008, 11, 43.
35. 1 Efforts to determine the position and extent of metabolism for compounds in this paper are under investigation and should yield further information as to any potential metabolic liability associated with the oxetan-3-yl group.